CEO hire signals private equity unlikely to buy PPD; analyst
PPD has named a new CEO and is now unlikely to be taken over by private equity because the deal environment has worsened, an equity analyst said.
Archives for September 19, 2011
Reformulation targeted in FDA unapproved drug plan
The FDA is targeting companies that reformulate drugs to evade enforcement as it tries to crackdown on the 1000s of products marketed without approval.
Pharma discharge checks called for to protect waterways
Researchers have called for closer monitoring of pharma manufacturing discharges after detecting endocrine disruption in fish downstream from a Sanofi plant.
Russian MoH OKs nearly 600 sites for trials
The Russian Ministry of Health (MoH) has cleared nearly 600 trial sites for clinical research, easing concerns that the reaccreditation process was taking too long.
Drug delivery round-up
in-PharmaTechnologist presents its round-up of the latest in the world of drug delivery, including news from Sanofi Pasteur, Haselmeier, Unigene, and Southwest Research Institute.
Frontage and Spaulding team on core lab services and China
Frontage Laboratories and Spaulding Clinical Research have teamed up to target China’s rapidly expanding contract research sector.
Berkshire Hathaway completes $9.7bn Lubrizol acquisition
Chemicals supplier Lubrizol was bought by Warren Buffet’s Berkshire Hathaway group last week in a deal worth $9.7bn (€7.1bn)